CHICAGO—The first drug to hold advanced uveal melanoma in check — doubling progression-free survival — was announced at the 2013 American Society of Clinical Oncology meeting in Chicago. Dr Richard Carvajal from Memorial Sloan-Kettering Cancer Center in New York presented results from a Phase II study with 98 patients randomised to receive an old drug, temozolomide, or selumetinib which inhibits the MEK pathway affected by GNAQ and GNA II gene mutations commonly found in this rare tumour. He discussed findings with Peter Goodwin.
You may also like...
Venetoclax Pro-Apoptotic Therapy Benefits Older Patients with Acute Myeloid Leukemia 19 Jan, 2018 Audio Journal of Oncology – June 7th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6 6 Jun, 2006 Audio Journal of Oncology Volume 16 Number 11 3 Jun, 2008 Is breast cancer screening oversold? 29 Mar, 2013
- Previous story Audio Journal of Oncology with Oncology Times, June 2013
- Next story Patients with oropharyngeal cancer: no HPV risk to spouses, partners
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014